bisolvon strong 1.6 mg/ml oraaliliuos
opella healthcare france sas - bromhexine hydrochloride - oraaliliuos - 1.6 mg/ml - bromiheksiini
lercanidipin hydrochlorid actavis 10 mg tabletti, kalvopäällysteinen
actavis group ptc ehf - lercanidipine hydrochloride - tabletti, kalvopäällysteinen - 10 mg - lerkanidipiini
lercanidipin hydrochlorid actavis 20 mg tabletti, kalvopäällysteinen
actavis group ptc ehf - lercanidipine hydrochloride - tabletti, kalvopäällysteinen - 20 mg - lerkanidipiini
solomet depot c. bupivacain. hydrochlorid. 40 mg/ml + 5 mg/ml injektioneste, suspensio
orion corporation - bupivacaine hydrochloride monohydrate, methylprednisolone acetate - injektioneste, suspensio - 40 mg/ml + 5 mg/ml - metyyliprednisoloni
natriumklorid braun cum glucos 4.5 mg/ml + 50 mg/ml infuusioneste
b. braun melsungen ag - natrii chloridum,glukoosi monohydricum - infuusioneste - 4.5 mg/ml + 50 mg/ml - elektrolyytit ja hiilihydraatit
minims oxybuprocaine hydrochloride 4 mg/ml silmätipat, liuos, kerta-annospakkaus
bausch + lomb ireland limited - oxybuprocaine hydrochloride - silmätipat, liuos, kerta-annospakkaus - 4 mg/ml - oksibuprokaiini
thallous ti-201 chloride 37 mbq/ml injektioneste
curium netherlands b.v. - 201tl-thallium-chloride - injektioneste - 37 mbq/ml - tallium(201tl)kloridi
sitagliptin / metformin hydrochloride accord
accord healthcare s.l.u. - metformin hydrochloride, sitagliptin hydrochloride monohydrate - diabetes mellitus, tyyppi 2 - diabeetilla käytettävät lääkkeet - for adult patients with type 2 diabetes mellitus:it is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination of sitagliptin and metformin. it is indicated in combination with a sulphonylurea (i. kolmen lääkkeen yhdistelmähoito) lisänä ruokavalion ja liikunnan ohella potilaille riittävästi hallinnassa heidän maksimaalinen siedetty annos metformiinia ja sulfonyyliureaa. it is indicated as triple combination therapy with a peroxisome proliferator-activated receptor gamma (pparγ) agonist (i. , a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a pparγ agonist. it is also indicated as add-on to insulin (i. , triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when stable dose of insulin and metformin alone do not provide adequate glycaemic control.
lercanidipine hydrochloride accord 20 mg tabletti, kalvopäällysteinen
accord healthcare b.v. - lercanidipine hydrochloride - tabletti, kalvopäällysteinen - 20 mg - lerkanidipiini
lercanidipine hydrochloride accord 10 mg tabletti, kalvopäällysteinen
accord healthcare b.v. - lercanidipine hydrochloride - tabletti, kalvopäällysteinen - 10 mg - lerkanidipiini